HIZENTRA (CSL Behring Australia Pty Ltd)
Product name
HIZENTRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
normal immunoglobulin
Registration type
EOI
Indication
HIZENTRA (solution for subcutaneous injection) is now also indicated for Immunomodulatory therapy in:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy after stabilisation with IVIg.